PDCD1 and melanoma: For example, ipilimumab (CTLA-4 inhibitor) and pembrolizumab (PD-1 inhibitor) have significantly reduced the risk of recurrences in trials and increased overall survival benefits in their use as adjuvant therapies in patients who completed surgical resection of melanoma lesions[17].